Detail Data
Volume (24h): 3,411,162 shares
P/E Ratio: 5.50
Forward P/E: -4.55
EPS: 0.48 USD
Forward EPS: -0.58 USD
Number of Shares: 157,544,000 shares
Market Capitalization: 415,916,192.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company CytomX Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a buy recommendation for CytomX Therapeutics stock. The current number of analysts covering this company is 5. The highest target price is 8 USD, while the lowest target price is 3.5 USD. The median target valuation set by analysts is 5 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of CytomX Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for CytomX Therapeutics stock is: buy
Number of Analysts: 5
Highest Target Price: 8 USD
Lowest Target Price: 3.5 USD
Median Target Price: 5 USD

Fundamental Indicators

Indicator Data
Total Revenue: 147,556,992.00 USD
Net Income: 41,603,000.00 USD
Price-to-Book (P/B): 8.49
PEG Ratio: /
Exchange: NasdaqGS
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 119
Country: United States

Where to Buy CytomX Therapeutics Stock?

You can purchase CytomX Therapeutics stock on the NasdaqGS under the ticker symbol: CTMX. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on CytomX Therapeutics Stock

Indicator Value
Company Revenue: 147,556,992.00 USD
EBITDA: 37,645,000.00 USD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization.
Earnings Per Share: 0.48 USD
Book Value Per Share: 0.31 USD
Total Cash: 79,886,000.00 USD
Total Cash per Share: 0.99 USD
Total Debt: 8,149,000.00 USD
Debt to Equity Ratio: 0.33
Quick Ratio 1.63
Current Ratio 1.73
Free Cash Flow -53,067,624.00 USD
Operating Cash Flow -81,229,000.00 USD
Gross Margins 100.00 %
EBITDA Margins 25.51 %
Operating Margins 44.43 %
Profit Margins 28.20 %
Return on Assets 15.9 %
Return on Equity -
Earnings Growth (1 year) 60.6%
Revenue Growth (1 year) 22.8 %
Quarterly Earnings Year-over-Year Growth 70.6 %
Market Capitalization 415,916,192.00 USD
Enterprise Value 141,103,216.00 USD
EV/Revenue 0.956
EV/EBITDA 3.748
Float Shares 60,985,977 shares
Shares Outstanding 157,544,000 shares
Held Percent Insiders 0.01 %
Held Percent Institutions 51.04 %
Shares Short 17,729,196
Shares Short Prior Month 9,569,066
Date Short Interest 2025-05-15
Short Percentage of Total Shares 11.25 %
Short Ratio 1.92
Beta 2.12
Short Percentage of Float 11.69 %
Implied Shares Outstanding 164,080,992

Frequently Asked Questions (FAQ)

According to our data, the company CytomX Therapeutics does not pay dividends yet, even in 2025.

CytomX Therapeutics shares are traded on the NasdaqGS stock exchange under the ticker: CTMX. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for CytomX Therapeutics shares is from a total of 5 analysts. The average target price prediction is 5 USD per share.

The total number of CytomX Therapeutics shares on the exchange is 157,544,000.00 shares, which at the current market capitalization gives the company a total valuation of 415,916,192.00 USD.